Alpha-emitter nanogenerators and daughter trapping
Actinium-225 releases four alpha particles as it decays, but the daughters escape and irradiate the kidneys and salivary glands. Nanocarriers try to hold them in place.
Overview
The therapeutic power of actinium-225 comes from its decay chain, but recoil energy ejects daughter nuclides from any chelator, causing off-target dose. Nanoparticle carriers (lanthanum phosphate, titanium dioxide, liposomes) and polymer cages are designed to retain daughters long enough for them to decay inside the tumour. Retention above 90% has been reported in animals; no such construct had reached human trials by 2026.
How it works
Encapsulating the parent nuclide in a solid-state or multi-shell carrier physically retains recoiling daughters, converting a leaky decay chain into a contained one.
- Could remove the main toxicity limit on actinium therapy
- Multiplies alpha dose per targeting event
- Compatible with existing targeting ligands
- No human data
- Nanoparticle biodistribution favours liver and spleen
- No trodden regulatory path for a radioactive nanomaterial
Latest papers
topQuery for this technology: (TITLE:"Alpha-emitter nanogenerators and daughter trapping" OR ABSTRACT:"Alpha-emitter nanogenerators and daughter trapping") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Alpha-emitter nanogenerators and daughter trapping, not a curated reading list.
Similar pages
not linked directly; found by shared links- TechnologyAuger-electron therapy
Shares Alpha vs beta emitters, Dosimetry, Targeted alpha therapy, Radioligand therapy (beta emitters) and the tags frontier, radical.
- TechnologyTotal-body PET for screening and ultra-low-dose imaging
Shares Dosimetry and the tag frontier.
- TechnologyRadio-antibody & radio-ADC
Shares Targeted alpha therapy, Actinium-225 and the tag frontier.
- TechnologyRadioligand plus DNA-repair inhibitor combinations
Shares Targeted alpha therapy, Radioligand therapy (beta emitters) and the tag frontier.
- IdeaAlpha-emitting PSMA therapy at first metastatic diagnosis
Shares Alpha vs beta emitters, Dosimetry, Targeted alpha therapy, Actinium-225.
- IdeaRegional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit
Shares Alpha vs beta emitters, Dosimetry, Targeted alpha therapy, Actinium-225.
- TermRelative biological effectiveness (RBE)
Shares Alpha vs beta emitters, Targeted alpha therapy, Actinium-225, Radioligand therapy (beta emitters).
- IdeaRecover legacy radium-226 sources worldwide as the feedstock for actinium-225
Shares TerraPower Isotopes, Targeted alpha therapy, Actinium-225, Radioligand therapy (beta emitters).